Mobile World Congress: SleepRate, provider of mobile health solutions for sleep deficit disorders, has announced the launch of an end to end mobile health application that monitors sleep to detect and treat non-medical sleeping problems. SleepRate is showcasing its mobile application at Mobile World Congress.
Wayne Giles, MD, director of the division of population health at the Centres for Disease Control and Prevention (CDCP) in the US, said a year ago: “Now CDCP has a very broad portfolio of surveillance data that specifically focus on sleep health.” He noted research performed around sleep in relation to obesity, chronic obstructive pulmonary disease, and cardiovascular disease, along with areas such as drowsy driving.
According to the CDCP the results of sleep deficiencies and disorders can be devastating, with a 45% higher risk of heart attacks and a 12% higher risk of death, making sleep deprivation and disorders a “public health epidemic”, he said.
SleepRate provides sleep monitoring and assessment to detect sleep deficiency disorders, to be followed by a personally tailored treatment programme to cure a wide spectrum of non-medical sleep deficit disorders. Its patented diagnostic technology uses sleep analysis algorithms that were FDA-cleared, while the therapeutic intervention is based on treatment protocols that were developed and validated at the Behavioural Sleep Division at Stanford University.
The result is an all-in-one solution offered by SleepRate that monitors sleep schedule, related habits, duration, quality, continuity efficiency and structure, snoring and environmental noises in the habitual sleep settings over six nights; diagnoses and reports any detected sleep deficits during the monitoring; and presents a personalised sleep improvement plan that provides the person with step by step sleep-related behavioural goals, as well as cognitive tasks, that will reboot sleep over a period of a few weeks.
SleepRate research showed that insomnia severity score decreases in insomniacs who completed the programme, while the time it takes to fall asleep decreased by 27% and the number of times a person is awakened during the night decreased by 41%.
The global sleeping aids market was valued at $54 billion in 2014 and is expected to grow to $76 billion by 2019 [BBC Research]. Furthermore, with studies suggesting that sleeping pills can increase the risk of Alzheimer’s [University of Washington School of Pharmacy], many sleep deficit disorder sufferers are seeking out other treatments for a condition that has a $100 billion a year impact on the US economy and costs an extra $1500 a year in healthcare utilisation for each poor sleeper.
“Millions of people around the world are suffering from sleep deficit disorders, which represent a major health concern with potential devastating consequences,” said Dr. Anda Baharav, founder and CEO of SleepRate.
“Sleep is not a luxury and the failure to get the sleep the body needs can lead to numerous major health risks. SleepRate monitors and detects sleep deficits in both those actively seeking treatments for a known sleep problem, as well as for those who may not be aware that they suffered from sleep deprivation at all, providing them with a personalised treatment plan that allows to get the good night sleep they need,” Baharav added.